Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

• Published in: Pediatric blood & cancer Vol. 63; no. 9; pp. 1552 - 1556
• Main Authors: Lee, Jun Ah, Jeon, Dae-Geun, Cho, Wan Hyeong, Song, Won Seok, Yoon, Hoi Soo, Park, Hyeon Jin, Park, Byung Kiu, Choi, Hyoung Soo, Ahn, Hyo Seop, Lee, Ji Won, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Koh, Kyung-Nam, Im, Ho Joon, Seo, Jong Jin, Lim, Yeon Jung, Baek, Hee Jo, Kook, Hoon
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01-09-2016; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - mortality; Child; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; docetaxel; Female; gemcitabine; Hematology; Humans; Male; Oncology; osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - mortality; Pediatrics; recurrent; refractory; Retrospective Studies; Taxoids - administration & dosage; Taxoids - adverse effects; refractory; gemcitabine; docetaxel; recurrent; osteosarcoma
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.26058

ABSTRACT
Background
Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated.
Methods
Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m2 on days 1 and 8) and DOC (100 mg/m2 on day 8), were retrospectively reviewed.
Results
GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m2 GEM than in patients receiving 675 mg/m2 (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1‐year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04).
Conclusions
Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.